ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2600

Assessment of Quality of Care for Incident Lupus Nephritis in the U.S. Medicaid Population

Jinoos Yazdany1, Candace H. Feldman2, Jun Liu3, Michael M. Ward4, Michael A. Fischer5 and Karen H. Costenbader6, 1Medicine, University of California, San Francisco, San Francisco, CA, 2Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 3Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Harvard Medical School, Boston, Boston, MA, 4Bldg 10 CRC Rm 4-1339, NIAMS/NIH, Bethesda, MD, 5Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, 6Rheumatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Quality of care and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Quality Measures and Innovations in Practice Management and Care Delivery

Session Type: Abstract Submissions (ACR)

Background/Purpose: The contribution of uneven health care quality to racial/ethnic and socioeconomic disparities in lupus nephritis outcomes is unknown.  We aimed to assess performance on two health care quality measures in a nationwide cohort of Medicaid recipients with incident lupus nephritis.

Methods: We used Medicaid analytic extract (MAX) data from 2000-2004 containing person-level files on Medicaid eligibility, utilization and payments.  We identified patients meeting a validated administrative data definition of incident lupus nephritis, and used this group as the denominator population for both quality metrics (QMs).  Numerator components included:

QM1 :  Induction therapy with glucocorticoids and another immunosuppressant (azathioprine, mycophenolate mofetil, mycophenolic acid, cyclophosphamide, cyclosporine A, or tacrolimus)

within 30 days of lupus nephritis onset.

QM2 : Use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARB)

within 90 days of lupus nephritis onset. 

We used multivariate logistic regression models to examine sociodemographic (age, sex, race/ethnicity), geographic (U.S. region), and health care (health professional shortage areas, HPSAs, from the Area Resource File) predictors of higher performance. In additional analyses, we extended the time period for both QMs to 365 days to assess whether performance improved with time. 

Results: 974 Medicaid recipients met the definition of incident lupus nephritis.   Mean age was 39 years (SD 12, range 18-64), 93% were female, and most were African American (African American 48%, White 27%, Hispanic 13%, Asian 6%).  Individuals were geographically dispersed (20% Midwest, 22% Northeast, 34% South, 24% West), and 41% resided in partial or complete HPSAs. Only 19.5% received care consistent with all numerator components of QM1; 25% of individuals received only steroids, and 13% received immunosuppressants alone. When the timeframe for QM1 was extended to one year, performance rose to 30%.  For QM2, 30% of individuals received an ACE/ARB within 90 days. When this timeframe was extended to one year, performance rose to 58%.  In multivariate logistic regression models, those living in the South were less likely to receive recommended therapy for lupus nephritis (QM1; OR 0.53, CI 0.28-0.99), while younger individuals were more likely to receive treatment (OR for 18-34 years versus referent 51-64 years 3.5, CI 1.6-7.6).  Individuals in the Midwest were less likely to receive an ACE/ARB (QM2; OR 0.52, CI 0.34-0.80), while African Americans were more likely (OR 1.7, CI 1.2-2.4).

Conclusion: These data suggest substantial gaps and delays in care for U.S. Medicaid patients with incident lupus nephritis.  A large number received steroid monotherapy or no immunosuppressant within one month, although performance improved by one year.  Use of ACE/ARBs was low in the first 90 days, but rose to 58% by one year.  Geographic differences were observed, with individuals in the South and Midwest being less likely to receive recommended care.  The contribution of state Medicaid policies, specialty care access, and drug coverage policies to these observed geographic differences warrants investigation.


Disclosure:

J. Yazdany,
None;

C. H. Feldman,
None;

J. Liu,
None;

M. M. Ward,
None;

M. A. Fischer,
None;

K. H. Costenbader,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-quality-of-care-for-incident-lupus-nephritis-in-the-u-s-medicaid-population/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology